Effect of Albumin on Clinical Function after Acute Intracerebral Hemorrhage among Hospitalized Patients in Neurology Department of Ahvaz Golestan Hospital, Iran

Document Type : Original Article


1 Department of Neurology, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.

2 General Practitioner


Background and Objective: The aim of this study was to evaluate the effect of the albumin in clinical function after acute intracerebral hemorrhage.
Subjects and Methods: The study was a double-blind clinical trial in two group of patient with  hemorrhagic stroke, including those with stroke occurred in the last 24 hours. The first group treated with albumin infusion with total dose of 1 g/Kg body weight for two hours per day and the second group was treated with normal saline with the same dose. The treatment duration was 7 days. Functional outcome of the first day, 8th days and 3 months after treatment were investigated on the basis of NIHSS. By Chi square and T-Test tatistical analyses and evaluation of the effectiveness of the intervention in the two groups were studied.
Results: Each arm of study contained 30 patients. Both groups were the similar in age, sex and risk factors. There were not significant difference in mortality rate) P=0.353(, hospitalization duration )P=0.343( and hematoma size before )P=0.596( and after )P=0.483( treatment in two groups. NIHSS of the first day )P=0.474( and after 3 months )P=0.095 following treatment did not show significant differences among both groups. However, the result at the 8th day of treatment showed significant differences (P=0.025).
Conclusion: The findings of thisstudy confirmed that, intravenous albumin used in the initial days in the patient with hemorrhagic stroke would improve short-term clinical and functional outcome, but this positive effect is diminished in the long-term.


1-Jose Biller, Betsy B. Love, and Michael J. Schneck. In:Bradley's Neurology in Clinical Practice. 5th ed. Philadelphia: Butterworth-Heinemann/Elsevier; 2008
2-Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. New Eng J Med 2008;359(13):1317-29.
3-Sacco RL. chapter 41. In: Rowland LP, editor. 11th ed. Merritt's neurology. Philadelphia: Lippincott Williams & Wilkins, 2005.
4-Kidwell CH, Menon R, Burgess R. Albumin for intracerebral hemorrhage intervention (ACHIEVE). Available at: URL: http://www. clinical trials.gov; identifires.gov; identifier number : NCT00990509
5-Norrving, B. Cerebral hemorrhage. In: Ginsberg M, Bogousslavsky J, eds. Cerebrovascular disease: pathophysiology, diagnosis, and management. Malden: Blackwell Science; 1998
6-Fogelholm R, Nuutila M, Vuorela AL. Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985-89: incidence, case fatality rate, and functional outcome. J Neurol Neurosurg Psychiatry 1992;55(7):546–52
7-Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, Ginsberg MD. Posttreatmentwith high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats. J Neurotrauma 1999;16(6):445–53.
8-Giroud M, Gras P, Chadan N, Beuriat P, Milan C, Arveux P, et al. Cerebral haemorrhage in a French prospective population study. J Neurol Neurosurg Psychiatry 1991;54(7):595-8.
9-Thrift AG, McNeil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998;31(6):1223-9.
10-Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33(4):1077–84.
11-Dziedzic T, Pera J, Slowik A, Gryz-Kurek EA, Szczudlik A. Hypoalbuminemia in acute ischemic stroke patients: frequency and correlates. Eur J Clin Nutr 2007;61(11):1318-22.
12-Famakin B, Weiss P, Hertzberg V, McClellan W, Presley R, Krompf K, et al.  Hypoalbuminemia predicts acute stroke mortality: Paul Coverdell Georgia Stroke Registry. J Stroke Cerebrovasc Dis 2010;19(1):17-22.
13-Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32(2):553- 60.
14-Suarez JI, Shannon L, Zaidat OO, Suri MF, Singh G, Lynch G, et al. Effect of human albumin administration on clinical outcome and hospital lost in paitents with subarachnoid hemorrhage. J Neurosurg. 2004;100(4):585-90.
15-Belayev L, Saul I, Busto R, Danielyan K, Vigdorchik A, Khoutorova L, et al. Albumin treatment reduces neurological deficit and protect blood brain barrier integrity after acute intracortical hematoma in the rat. Stroke 2005;36(2):326-31.